Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA180819)
Article History
Received: 8 November 2021
Revised: 12 November 2021
Accepted: 22 November 2021
First Online: 7 January 2022
Conmpeting interests
: MO is a consultant for Daiichi Sankyo, Biosight, and Merck and is on independent data safety monitoring boards for Celgene and Glycomimetics. RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. CStone Pharmaceuticals, NexImmune Inc. and Prolacta Bioscience; advisor to Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.
Free to read: This content has been made available to all.